Pfizer Dodges Challenge to Its Board

Pfizer Gets Breather From Starboard’s Ongoing Assault
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by its current leadership. But Bloomberg reports it has missed the deadline for nominating a director to the pharma’s board.
Pfizer Dodges Challenge to Its Board in Fight With Starboard
Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter.
Pfizer avoids board nominations from Starboard as proxy fight rolls on: Bloomberg
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the activist investor’s unfolding proxy fight. | Activist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan.
Starboard did not nominate Pfizer board members, Bloomberg says
Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting
Starboard refrains from nominating directors to Pfizer's board - Bloomberg
Pfizer Inc. (NYSE:PFE) has temporarily avoided a standoff with activist investor Starboard Value LP. According to Bloomberg sources, Starboard did not put forward any nominations for Pfizer's board before the January 25 deadline for the pharmaceutical company's annual meeting in April.
Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
Pfizer Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
FiercePharma1d
Pfizer shells out nearly $60M to resolve Nurtec kickback claims inherited in Biohaven buyout
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...
What's Going On With Pfizer Stock Monday?
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...
Pharmaceutical Technology on MSN1d
Pfizer settles Biohaven kickback claims case for $59.7m
Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
Pfizer price target lowered to $29 from $30 at Citi
Citi analyst Geoff Meacham lowered the firm’s price target on Pfizer (PFE) to $29 from $30 and keeps a Neutral rating on the shares. Ahead of ...
Is Pfizer Stock a Buy?
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
Zacks.com on MSN4h
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) closed the latest trading day at $26.75, indicating a -0.41% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...